TCGA-CQ-A4C9-01A-11R-A24Z-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.400
- E2F_TARGETS+0.290
- OXIDATIVE_PHOSPHORYLATION+0.280
- ADIPOGENESIS+0.220
- BILE_ACID_METABOLISM+0.220
- PEROXISOME+0.210
- FATTY_ACID_METABOLISM+0.180
- G2M_CHECKPOINT+0.150
- MYC_TARGETS_V1+0.140
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.130
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- IL6_JAK_STAT3_SIGNALING-0.410
- TGF_BETA_SIGNALING-0.410
- UV_RESPONSE_DN-0.410
- PROTEIN_SECRETION-0.400
- HYPOXIA-0.370
- INFLAMMATORY_RESPONSE-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- COMPLEMENT-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.903 |
| 2 | TCGA-CN-A63U-01A-11R-A30B-07 | — | — | 0.866 |
| 3 | TCGA-P3-A6T6-01A-11R-A34R-07 | — | — | 0.857 |
| 4 | TCGA-CN-A6V7-01A-12R-A34R-07 | — | — | 0.856 |
| 5 | SRR25043617 | — | — | 0.854 |
| 6 | ERR2208933 | — | — | 0.853 |
| 7 | 63bab58e-1dfd-43df-8188-4b8d766913f3 | — | — | 0.852 |
| 8 | TCGA-E9-A54Y-01A-11R-A466-07 | — | B | 0.851 |
| 9 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.848 |
| 10 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |